Hot Life Science Investor Mandate 1: Family Office Seeking Platform Technologies

30 Jan

A single family office in the US is currently seeking to invest in platform technologies. The firm manages approximately $4 billion in assets with $600 million dedicated to life science investing. The family office is currently allocating out of its 7th fund, a $100 million dollar fund that closed in 2012. Typical investments range from $1-$2 million to $25-$40 million depending on deal stage. The firm prefers to make controlling investments and has an average holding period of approximately 8 years.

The family office primarily invests throughout the United States although they have made investments outside the US in the past. Companies In the therapeutic space developing platform technologies are of primary interest. Companies developing single assets or medical devices are not of interest. The family office is open to considering platform companies from all stages, sizes and indications although they are especially interned in areas of Cell and Gene Therapy, Synthetic Biology, CNS, Neurology, and Orphan Indications.

The family office is looking for companies with experienced management teams and is open to investing in both public and privately held companies.  Companies that previously failed a trial or have incomplete management teams and need re-organization are also of interest. The family office is a very long term hands on investor that looks to add value in addition to capital, thus it almost always acts as the lead in any investment rounds.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: